CTOs on the Move

MY01

www.my01.io

 
MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.my01.io
  • 400 Boul de Maisonneuve Ouest Suite 700
    Montréal, QC CAN H3A 1L4
  • Phone: 855.799.6901

Executives

Name Title Contact Details

Similar Companies

Associated Radiologist P.A.

Associated Radiologist P.A. is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Care Medical Equipment

Care Medical Equipment is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ThermoTek

"ThermoTek has been the leader in thermal management technologies for more than 10 years. Our innovative ""building blocks"" for thermal management solutions include patented power supplies and temperature controllers, thermoelectric coolers,"

Teleflex

Teleflex is a global provider of medical devices used in critical care and surgery. We serve healthcare providers with specialty devices for vascular access, general and regional anesthesia, urology, respiratory care, cardiac care and surgery.

Armetheon

Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ability to offer peace of mind to patients while benefitting physicians, who may wish to reduce safety concerns, side effects and adverse events for their patients.